Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery.

International journal of pharmaceutics

Volumn 456, Issue 1, 2013, Pages 223-234

  Wang, Xiaohong ^a   Lin, Yan ^b   Zeng, Yingchun ^b   Sun, Xun ^b   Gong, Tao ^b   Zhang, Zhirong ^b  

^a SICHUAN UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSAMINE; MYCOPHENOLIC ACID;

ANIMAL; BIOAVAILABILITY; BLOOD; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; RAT; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD UREA NITROGEN; CELL LINE; CELL SURVIVAL; CREATININE; DRUG DELIVERY SYSTEMS; GLUCOSAMINE; HUMANS; KIDNEY; MALE; MICE; MYCOPHENOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TISSUE DISTRIBUTION;

EID: 84899035774     PISSN: None     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.07.064     Document Type: Article

References (33)

1. S.J. Chadban E.M. Briganti P.G. Kerr D.W. Dunstan T.A. Welborn P.Z. Zimmet R.C. Atkins Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study J. Am. Soc. Nephrol. 14 2003 S131 S138
2. J. Chen R.P. Wildman D. Gu J.W. Kusek M. Spruill K. Reynolds D. Liu L.L. Hamm P.K. Whelton J. He Prevalence of decreased kidney function in Chinese adults aged 35–74 years Kidney Int. 68 2005 2837 2845
3. K.H. Choi S.I. Kim S.K. Shin J.I. Moon Y.S. Kim H.Y. Lee D.S. Han K. Park Renal replacement therapies in the elderly: renal transplantation and continuous ambulatory peritoneal dialysis Transplant. Proc. 32 2000 1814
4. E.I. Christensen J. Gliemann S.K. Moestrup Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein J. Histochem. Cytochem. 40 1992 1481 1490
5. J. Coresh B.C. Astor T. Greene G. Eknoyan A.S. Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am. J. Kidney Dis. 41 2003 1 12
6. Q. Geng X. Sun T. Gong Z.R. Zhang Peptide–drug conjugate linked via a disulfide bond for kidney targeted drug delivery Bioconjugate Chem. 23 6 2012 1200 1210
7. H.L. Hillege W.M.T. Janssen A.A.A. Bak G.F.H. Diercks D.E. Grobbee H.J.G.M. Crijns W.H.V. Gilst D.D. Zeeuw P.E.D. Jong Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity J. Intern. Med. 249 2001 519 526
8. K. Iseki The Okinawa Screening Program J. Am. Soc. Nephrol. 7 Suppl. 2 2003 S127 S130
9. A.D. Kirk Location, location, location: Regional immune mechanisms critically influence rejection Nat. Med. 8 2002 6
10. G.A. Knoll I. MacDonald A. Khan C.V. Walraven Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation J. Am. Soc. Nephrol. 14 2003 2381 2386
11. H.D.D. Koo V.S. Fuggle Impact of ischemia/reperfusion injury and early inflammatory responses in kidney transplantation Transplant. Rev. 14 2000 210 224
12. H.D.D. Koo V.S. Fuggle Chemokines in ischemia/reperfusion injury Curr. Opin. Organ Tranplant. 7 2002 100 106
13. A.S. Levey K.U. Eckardt Y. Tsukamoto A. Levin J. Coresh J. Rossert D. De Zeeuw T.H. Hostetter N. Lameire G. Eknoyan Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 67 2005 2089 2100
14. Y. Lin X. Sun T. Gong Z.R. Zhang Prednisolone succinate–glucosamine conjugate: synthesis, characterization and in vitro cellular uptake by kidney cell lines Chin. Chem. Lett. 23 2012 25 28
15. K. Morimoto M. Kondo K. Kawahara H. Ushijima Y. Tomino M. Miyajima J. Kimura Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis Pharm. Res. 24 2007 946 954
16. J. Nagai H. Tanaka N. Nakanishi T. Murakami M. Takano Role of megalin in renal handling of aminoglycosides Am. J. Physiol-Renal Physiol. 281 2001 337 344
17. E. Nieto E. Escudero E. Navarro M. Yanez-Mo A. Martin G. Perez de Lema F. Sanchez-Madrid F. Mampaso Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis J. Am. Soc. Nephrol. 113 2002 937 945
18. M. Oellerich M. Shipkova E. Schütz E. Wieland L. Weber B. Tönshoff V.W. Armstrong Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring Ther. Drug Monit. 22-1 2000 20 26
19. T. Okamoto S. Nakagawa Y. Tsutsumi The optimal molecular design of polymeric drug carriers and its application for renal drug targeting Gene Ther. Mol. Biol. 8 2004 221 230
20. R.P. Pelletier B. Akin M.L. Henry G.L. Bumgardner E.A. Elkhammas A. Rajab M. Fergusonr The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation Clin. Transplant. 17 2003 200 205
21. J. Prakash H.M. de Borst M.A. van Loenen-Weemaes M. Lacombe F. Opdam H. van Goor F.K.D. Meijer F. Moolenaar K. Poelstra J.R. Kok Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis Pharm. Res. 25 2008 10
22. A.C. Shirali M. Look W. Du E. Kassis H.W. Stout-Delgado T.M. Fahmy D.R. Goldstein Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival Am. J. Transplant. 11 2011 2582 2592
23. P. Stenvinkel Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease J. Intern. Med. 268 2010 456 467
24. J.A. Vassalotti L.A. Stevens A.S. Levey Testing for chronic kidney disease: a position statement from the National Kidney Foundation Am. J. Kidney Dis. 50 2007 169 180
25. L.T. Weber M. Shipkova V.W. Armstrong N. Wagner S.T. Ekkehard O. Mehls L.B. Zimmerhackl M. Oellerich T.N. Burkhard The pharmacokinetic–pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant J. Am. Soc. Nephrol. 13 2002 759 768
26. L.T. Weber M. Shipkova V.W. Armstrong N. Wagner S.T. Ekkehard O. Mehls L.B. Zimmerhackl M. Oellerich T.N. Burkhard Comparison of the emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy Clin. Chem. 48 3 2002 517 525
27. R.R. Weng C.E. Foster III L.L. Hsieh P.R. Patel Oral ulcers associated with mycophenolate mofetil use in a renal transplant recipient Am. J. Health-Syst. Pharm. 68 Apr 1 2011
28. N.A. Wolff B.C. Burckhardt G. Burckhardt M. Oellerich V.W. Armstrong Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney Nephrol. Dial. Transplant. 22 2007 2497 2503
29. Z.X. Yuan X. Sun T. Gong H. Ding Y. Fu Z.R. Zhang Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier J. Drug Target. 15 2007 269 278
30. Z.X. Yuan J.J. Li D. Zhu X. Sun T. Gong Z.R. Zhang Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting J. Drug Target. 19 2011 540 551
31. G. Zandman-Goddard Y. Shoenfeld Mycophenolate mofetil in animal models of autoimmune disease Lupus 14 Suppl. 1 2005 S12 S16
32. Z.R. Zhang Q. Zheng J. Han G.P. Gao J. Liu T. Gong Z.W. Gu Y. Huang X. Sun Q. He The targeting of 14-succinate triptolide–lysozyme conjugate to proximal renal tubular epithelial cells Biomaterials 30 2009 1372 1381
33. L.X. Zhang F. Wang L. Wang W.K. Wang B.C. Liu J. Liu M.H. Chen Q. He Y.H. Liao X.Q. Yu N. Chen J.E. Zhang Z. Hu F.Y. Liu D.Q. Hong L.J. Ma H. Liu X.L. Zhou J.H. Chen L. Pan W. Chen W.M. Wang X.M. Li H.Y. Wang Prevalence of chronic kidney disease in China: a cross-sectional survey The Lancet 379 2012 815 822